Viral Vectors

Browse and view ASGCT's viral vector-focused content on-demand. This resource is made available exclusively for ASGCT members.

Not an ASGCT Member? Join Today!

ASGCT membership unlocks incredible discounts and on-demand access to a rich archive documenting the history of cell and gene therapy. Take the next step in your career by becoming an ASGCT member.

Find Viral Vectors Content

"How to" with AAV Vectors

July 9, 2021
This event begins with a short introduction to gene therapy and continues into a very structured approach to AAV vectors. The AAV material presented begins at a basic level but ultimately progresses to a level where mid-career professionals feel very comfortable and early professionals are developmentally pushed. 🔒

AAV Integration Roundtable

August 18, 2021
During this virtual roundtable, experts discussed the status of AAV integration research, including analysis of recent clinical findings, to develop recommendations for risk assessment. 🔒

AAV Vector Design

February 16, 2022
During this session, speakers discuss cutting-edge concepts and methods in the design and development of AAV vectors. Individual presentations are followed by a panel discussion where the invited experts will be available to answer questions from attendees and opine about personal experience and perspectives in the field. 🔒

AAV Vectors

April 14, 2023
Dr. Phil Tai provides an introduction to gene therapy and then continues into a very structured approach to AAV vectors. 🔒

ASGCT + FDA: Immune Responses to AAV Vectors

January 24-25, 2023
Topics during this two-day event include appropriateness and utility of a companion diagnostic for assessing pre-existing immunity, requirements for immunogenicity testing, and more. 🔒

 

Immunological Responses to AAV Gene Therapy in Neurological Compartments

November 30, 2022
This session provides updates on the humoral and cellular immune responses, including the impact of vector design, purity, and dose; DRG toxicity and potential immunological mechanisms; and management of immunological responses with a focus on the nervous system and implications for re-dosing. 🔒

Lunch and Learn: How AAV Vectors Are Made

April 28, 2022
We often hear that gene therapies are complex and require a lot of time and money to make. But what does that really mean? Tune in to hear experts in the field help answer this question by walking us through the manufacturing process. 🔒

Risk Assessment of Lentiviral + AAV Gene Therapy Vectors

October 17, 2023
Join ASGCT's expert panel to discover cutting-edge technologies and assays for integration site profiling, clonality, and oncogenesis. 🔒

Cell and Gene Therapy Science Series: Short and Long Read Sequenzing for AAV Characterization

March 30, 2023
Dr. Lauriel Earley discusses defective-interfering particles and their potential impact on gene therapy outcomes, NGS methods to characterize DI particples, and a case study of an NGS pipeline for AAV. 🔒

2024

Breakthroughs in Muscular Dystrophy

November 19-20, 2024 | Chicago, IL

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.